Nucleoside compounds and compositions thereof

    公开(公告)号:US06903079B2

    公开(公告)日:2005-06-07

    申请号:US10320780

    申请日:2002-12-16

    摘要: The invention provides a novel class of substituted nucleoside derivatives having the formula: A-Z1-L-Z2-G wherein: A and G are connected via Z1 and Z2 respectively, to a linker, L; and A is: wherein: X1 and X2 are N; X3 is —N═CH; R1 and R2 are independently H, alkyl, NH2, OH, SH, Cl, NHR9, or N═NR9, where R9 is alkyl, aryl, or arylalkyl; R5 and R6 are independently alkyl, or R5 and R6 taken together form a —C(CH3)2— group; Z1 is —CH2O—, —CH2NR10—, —CH2NR10C(O)—, —CONR10—, —CO2—, —CH2NHCONH—, —CH2—, —CH2NHCSNH—, —CO—, —CH2CO2—, —NHCO2—, —S—, —SO2—, —CH2S—, or —SO—; Z2 is —NR10CO—, —C(O)NR10—, —NHCONH—, —OC(O)—, —C(O)O—, NHCS, —CSNH—, —NHCSNH—, —O—, —CO—, —OCO—, —OCONH—, —NH—, —CH2—, —CH—alkyl—, —NHCO2—, —S—, —SO2—, CS—, or —SO—; L is H, O, S, C1-15 alkylene chain optionally substituted in one or more positions, a 5, 6 or 7 membered carbocycle, piperidine, piperazine, pyrole, imidazole, benzimidazole, tetrazoles, indole, isoquinoline, quinoline, or pyrrolidine, any of the 5, 6 or 7 membered carbocycle, piperidine, piperazine, pyrole, imidazole, benzimidazole, tetrazoles, indole, isoquinoline, quinoline, or pyrrolidine groups being unsubstituted or substituted with one or more lower alkyl, hydroxyl, keto, amino, aminoalkyl, halo, or alkoxy groups, provided that L is not H when Z1 is O, and when L=H, Z2 and G are absent; and G is H, OH, SH, NH2, CO2H, unsubstituted or substituted alkyl, aryl, alkylaryl, carbocyclic, biphenyl, piperidine, piperazine, pyrole, imidazole, benzimidazole, tetrazole, indole, isoquinoline, quinoline, isoindolinyl, tetrahydroindolinonyl, phthalimidyl, or pyrrolidine. Pharmaceutical compositions, and methods of making and using the compounds, or pharmaceutically acceptable salts, hydrates, or mixtures thereof are also described.

    Pyridyl-substituted porphyrin compounds and methods of use thereof

    公开(公告)号:US20080009473A1

    公开(公告)日:2008-01-10

    申请号:US11880068

    申请日:2007-07-19

    IPC分类号: A61K31/555 A61P39/06

    摘要: The present invention relates to Pyridyl-Substituted Porphyrin Compounds, compositions comprising an effective amount of a Pyridyl-Substituted Porphyrin Compound and methods for treating or preventing injury due to exposure to a reactive species, erectile dysfunction due to surgery, lung disease, hyperoxia, neurodegenerative disease, liver disease, myocardial damage during cardioplegia, an inflammatory condition, a reperfusion injury, an ischemic condition, a cardiovascular disease, diabetes, a diabetic complication, cancer, a side effect of cancer chemotherapy, or a radiation-induced injury, or to prolong the half-life of an oxidation-prone compound, comprising administering to a subject in need thereof an effective amount of a Pyridyl-Substituted Porphyrin Compound.

    Pyridyl-substituted porphyrin compounds and methods of use thereof
    10.
    发明授权
    Pyridyl-substituted porphyrin compounds and methods of use thereof 失效
    吡啶基取代的卟啉化合物及其使用方法

    公开(公告)号:US07432369B2

    公开(公告)日:2008-10-07

    申请号:US11090447

    申请日:2005-03-25

    IPC分类号: C07B47/00 C07D487/22

    摘要: The present invention relates to Pyridyl-Substituted Porphyrin Compounds, compositions comprising an effective amount of a Pyridyl-Substituted Porphyrin Compound and methods for treating or preventing injury due to exposure to a reactive species, erectile dysfunction due to surgery, lung disease, hyperoxia, neurodegenerative disease, liver disease, myocardial damage during cardioplegia, an inflammatory condition, a reperfusion injury, an ischemic condition, a cardiovascular disease, diabetes, a diabetic complication, cancer, a side effect of cancer chemotherapy, or a radiation-induced injury, or to prolong the half-life of an oxidation-prone compound, comprising administering to a subject in need thereof an effective amount of a Pyridyl-Substituted Porphyrin Compound.

    摘要翻译: 本发明涉及吡啶基取代的卟啉化合物,包含有效量的吡啶基取代的卟啉化合物的组合物和用于治疗或预防由于暴露于反应性物质引起的损伤,由于手术引起的勃起功能障碍,肺部疾病,高氧,神经变性 疾病,肝脏疾病,心脏停搏期间的心肌损伤,炎症状况,再灌注损伤,缺血状况,心血管疾病,糖尿病,糖尿病并发症,癌症,癌症化疗的副作用或辐射诱发的损伤,或 延长易氧化化合物的半衰期,包括向有需要的受试者施用有效量的吡啶基取代的卟啉化合物。